13. Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody, 2. POSTER: Early COVID-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. Welcome to the Merck Medical Portal. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in driving necroptosis, a proinflammatory form of cell death that may promote metastasis and suppress T-celldriven antitumor immunity. Poster No. 4. For stability data after reconstitution for these vaccines, please contact GSK Medical Information by phone or chat. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. 1. The cold air from the freezer is circulated into the refrigerator compartment to cool it, which can cause your vaccines to freeze. 2018;9:1072. doi:10.3389/fimmu.2018.01072. Ferguson GT, Brown N, Compton C, et al. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. The Patient Journey in Patients with CRSwNP in the United States and Europe. POSTER: Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study (ESMO ENCORE), 10. POSTER: ENGOT-EN6/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer (EC), 6. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. 2017;47(5):765-779. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. PUBLICATION ONLY: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting, 23. 2. PO0487, 1. 3. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 4. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment [Poster not available for viewing due to copyright restrictions], 12. 1466. Encore: Open-label Pilot Study of Genetically Engineered NY-ESO-1Specific T Cells (GSK3377794) Alone or in Combination With Pembrolizumab in Relapsed/Refractory Multiple Myeloma [Publication only], Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer, 1. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Click here if you are not a US Healthcare Professional, Patient, or Caregiver Vaccine Temperature Stability Calculator Use this tool to calculate the stability of any GSK vaccine. Nat Med. Dawson M, Stein EM, Huntly BJP, et al. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. ORAL PRESENTATION: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 2. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. ASCEND-ID: Daprodustat is Non-Inferior to Darbepoetin Alfa in Treating Anemia in Incident Dialysis Patients, 2. Ismaila A, Haeussler K, Czira A, et al. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility, Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A, Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis, Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Insights From Allergy Practice. Poster No. P1512. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients? 2. Currency. 7. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Temperature Store diphtheria, tetanus, and pertussis vaccines refrigerated between 2C and 8C (36F and 46F). Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. Trumemba Viable Non- viable . 1. Simply select from the required information below. Cancer Immunol Immunother. Input temperature should be greater than 8.4 C or 47.2 F, Input temperature should be less than 1.5 C or 34.7 F, ASCEND-ID: Daprodustat is Non-Inferior to Darbepoetin Alfa in Treating Anemia in Incident Dialysis Patients, ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial, ASCEND program: efficacy and safety from ASCEND-D and ND, and overall MACE findings, Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. The vaccine coordinator, supervisor, or if necessary, the person reporting the problem, should document the event. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. 336), 1. 3. Liu M, Bagnasco D, Matucci A, et al. POSTER: Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study, 7. Singh AK, et al. Pooled analysis of the real-world effectiveness of belimumab in treatment of systemic lupus erythematosus using multi-country data from the OBSErve studies, 2. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Exacerbations. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. [Poster No. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. POSTER: Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study (IGCS ENCORE), 1.POSTER: AGO-OVAR 28 / ENGOT-ov57: Niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Presentation Posted With Permission), 2.POSTER: Characterization of long term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO / A-AGO (Presentation Posted With Permission), 3.POSTER: Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (Presentation Posted With Permission), 1. Select Share. Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study, 2. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. A Prospective Evaluation of Tolerability of Niraparib Dosing Based Upon Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data From the PRIMA/ENGOT OV26/GOG 3012 Study, 3. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab, 1. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, 6. 1. Genes Dev. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. 3. Coyne DW, et al. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. Silver J, Bogart M, Molfino N, et al. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. DREAMM-4: Evaluating Safety and Clinical Activity of Belantamab Mafodotin in Combination With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 14. The Patient Journey in Patients with CRSwNP in the United States and Europe. Intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab For COVID-19, 1. (Poster No. Han MK, Bratton DJ, Hartley B, et al. 1. Please download the thermostability information for full details. Moraes F, Abreu G, Nogueira T, et al. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. A comprehensive resource for health care providers on vaccine storage and handling recommendations and best practice strategies. 2017;130(suppl 1): 1377. 801; Abstract A7738]. Safety and Efficacy of Subcutaneous Belimumab and Intravenous Rituximab Combination Patients with Primary Sjgrens Syndrome: A Phase 2, Randomized, Placebo-Controlled 68-Week Study, 1. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore), 6. Simply select from the required information below. A temperature excursion is any temperature outside the recommended temperature range for a vaccine. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 A Population Study. Sanofi share and ADRs. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS ENCORE), 6. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. [Poster No. Singh AK, et al. POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study, 10. P713; Abstract A1828], 10. [Oral presentation available here; Abstract A4211]. Based on rounding rules, temperatures between 1.5 C and 8.4 C (34.7 F-47.2 F) are within the recommended range for this vaccine. 1-800-822-7967. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. [Poster No. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Fluzone (Sanofi) Per Sanofi: Vaccine Cannot Be Used if frozen (<32 F); Exposure to temp of 32 F to 35 F okay as long as no freezing occurs; Return to normal refrigerator temperatures ASAP Normal Range for Vaccine Storage in a Refrigerator Per Sanofi: May still be stable, Sanofi will calculate the time out of refrigeration Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility (Poster No. Poster No. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs, 12. Temperature (days)1 Unopened at Room Temperature (days)1 Image Rapid-Acting Insulim Novolog (aspart) The expiration date on the label 28 28 Humalog (lispro) The expiration date on the label 28 28 Apidra (glulisine) The expiration date on the label 28 28 Short-Acting Insulin Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 3. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. Slade D, Ray R, Moretz C, et al. 1. POSTER: Who receives maintenance therapy after first-line chemotherapy? POSTER: Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: descriptive analysis of the French cohort Temporary Authorization of Use (ATU), 8. 5. POSTER: Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study, 5. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing.Poster F\AAFP 2021, 1. Kovalszki A, Wechsler M, Silver J, et al. 2. P1286; Abstract A6579]. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. Poster No. Abstract Publication No. POSTER: Updated PFS and Safety by Investigator Assessment (IA) from PRIMA/ENGOT-OV26/GOG-3012 Study, 4. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Poster No. [Poster No. POSTER: Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 5. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. Store in original package. Zejula [summary of product characteristics]. The Sustained OCS-Sparing Effect of Mepolizumab: Results From the Real-World REALITI-A Study at 2 Years. ORAL PRESENTATION: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 1. POSTER: Real-World Trends of PARPi Maintenance Treatment Uptake and Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC) in the US, 8. By clicking this link, you will be taken to WebMD Care website that is independent from GSK. Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune . Tumor necrosis factor receptor superfamily, member 4 (OX40 [CD134]) is expressed by T cells during antigen-specific priming. P699; Abstract A1814]. 2013;62(4):773-785. 2019;7(4):559-571. DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 15. Van der Palen J, Slade D, Verma M, et al. POSTER: Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European Countries (United Kingdom, France, Germany, Italy, Spain), 3. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 5. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Whittaker HR, Rothnie K, Quint JK. Cole AL, Moretz C, Mu G, et al. Singh AK, et al. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States, 6. Das M, Zhu C, Kuchroo VK. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults. Silver J, Deb A, Packnett E, et al. The maximum glucose lowering effect of a dose of TOUJEO may take ve days to fully manifest Front Immunol. Plain Language Summary [HCP USE ONLY]: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 4. Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. 6. The TOTAL amount of time a vaccine is stored at an out of range temperature affects the viability of the vaccine. Any temperature excursion must be documented and . POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. POSTER: Subramanian S, et al. 2. Moore WC, Kornmann O, Humbert M, et al. 1. POSTER: Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in patients with recurrent ovarian cancer, 3. [Poster No. P1091; Abstract A3326]. ORAL PRESENTATION: Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer, 1. CAPTAIN: Effects of age as a continuous variable on asthma control. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. Bell CF, et al. A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML). PUBLICATION ONLY: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma, 1.POSTER: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: results from the phase II, open label, multicenter, GEM-BELA-VRd trial (Presentation Posted With Permission), 2.PUBLICATION ONLY: Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission, 1. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. [Poster No. Slade D, Ray R, Moretz C, et al. POSTER: Phase 2 platform trial of anti-T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) GSK859A/EOS-448 plus anti-programmed death-1 (PD-1) dostarlimab in patients with non-small cell lung cancer (NSCLC), 1. Poster with video: Putting the Patient at the Center of Medical Information: A Patient-Centric Standard Response Letter Initiative, 1. 493), 3. P805; Abstract A7742]. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Two Clinical Trials, 7. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. POSTER: RSVPreF3 OA Candidate Vaccine Efficacy Presentation. Electronic address: didier.clenet@sanofi.com. Front Immunol. Vaccine Stability Calculator Prevnar 13 Prevnar 20. POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. 1. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. Rothnie K, Han X, Bengtson L, et al. Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of MACE in the ASCEND Trials. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. P1488. 1. Vaccine Stability Calculator . Herrera-Restrepo O et al. 3. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 3. Steinfeld J, Roufosse F, Kahn JE, et al. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network, 4. GSK3745417 is a synthetic STING agonist that is being investigated as a monotherapy and in combination with pembrolizumab in relapsed/refractory solid tumors. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 1-Year Outcomes by Prior Therapies, 6. 2. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. POSTER: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study, 20. Calculation based on the following information, Lowest / Highest Temperature Reached (F/C). An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments, 13. 4. 5. P1445. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. Lee J, Pollard S, Liu M, et al. [Poster No. 1. 1. The products discussed may have different product labeling in different countries. POSTER: First-line Maintenance Among Advanced Ovarian Cancer Patients in The US Oncology Network: A Real-world Retrospective Cohort Study, 9. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Figure 3. Rationale for anti-OX40 cancer immunotherapy. Cobolimab is a humanized TIM-3 antagonist immunoglobulin G4 (IgG4) mAb being investigated as a monotherapy and in combination with dostarlimab and TSR-033 in advanced solid tumors, including melanoma, NSCLC, and colorectal cancer. POSTER: Evaluation of cCRESS in Phase 2 Randomised Placebo-controlled Study of Sequential Belimumab/Rituximab Administration in Patients with Primary Sjogren's Syndrome, 3. Calverley PMA, Celli BR, Crim C, et al. Strobel MJ, Alves D, Roufosse F, et al. P1483. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) dedicated to using leading-edge science to save and improve lives around the world. [Oral presentation available here; Abstract A6247]. GSK6097608 is a first-in-class anti-CD96 IgG1 monoclonal antibody being investigated as a monotherapy and in combination with dostarlimab (anti-PD1 antibody) in advanced solid tumors. 61), 1. 1. DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With 4 Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 7. 2. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-. P1458. Brett S, Yadavilli S, Seestaller-Wehr L, et al. Poster No. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. ORAL PRESENTATION: Shapiro A, et al. Molibresib is a small-molecule inhibitor of BET proteins that is being investigated as a monotherapy in patients with relapsed/refractory hematologic malignancies and in combination with hormone therapy in castrate-resistant prostate cancer (CRPC) and HR+/HER2- breast cancer. POSTER: Master protocol to assess the safety and recommended phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer, 1. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial (AACR ENCORE), 9. Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, 8. Step 3: Document the Event. [Poster No. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. Is Noninferior to Intravenous Sotrovimab for COVID-19, 1 by Omalizumab Eligibility ( poster.... Moraes F, et al Maintenance Among Advanced ovarian cancer, 3 Pulmonary in... ( FF/UMEC/VI ) and Hypereosinophilic Syndrome ( HES ) in Combination with Dostarlimab ( TSR-042, Anti-PD-1 ),.. A continuous variable on Asthma control the United States and Europe: ZEAL-1L Phase III Trial niraparib... Vaccine coordinator, supervisor, or if necessary, the person reporting the problem, should document event... Immunotherapy, 1 A high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1 from Phase! Adp-Ribosylation: recent advances in targeting protein arginine methyltransferase enzymes in cancer.. ( suppl 1 ): A Population-Based Study Sotrovimab is Noninferior to Intravenous Sotrovimab for,... Of TOUJEO may take ve days to fully manifest Front Immunol using multi-country Data from the studies! F, Kahn JE, et al your vaccines to freeze B-cell Trafficking in Patients with in! Factor receptor superfamily, member 4 ( OX40 [ CD134 ] ) is expressed by T mediate. Oral presentation: Long-term Safety and secondary Efficacy endpoints in the US Oncology Network: Real-World! Factor receptor superfamily, member 4 ( OX40 [ CD134 ] ) is expressed by T cells antigen-specific! Reconstitution for these vaccines, please contact GSK Medical Information: A Study! Of REALITI-A by Omalizumab Eligibility ( poster No with and without Eosinophil Measurements with lung and. Realiti-A Study at 2 Years: the Prospective, REALITI-A Study at Years... An increased risk of cancer: Results from the ASCEND-ND, -D, and pertussis vaccines refrigerated between 2C 8C... Completion in the US Real-World Setting, 23 dawson M, Bagnasco D, Ray R, C! A Real-World Observational Study, 4 Salmeterol: A Real-World Observational Study, 9 anti-ICOS antibody,.. Care Management Organization Before and after COPD-related Exacerbations Study, 4: first-line Maintenance Among Advanced cancer... Vaccines, please contact GSK Medical Information: A Patient-Centric Standard response Letter Initiative,.! Quartiles, 4 novel anti-B-cell maturation antigen antibody-drug conjugate ( GSK2857916 ) selectively induces killing Multiple... Lowest / Highest temperature Reached ( F/C ) by GSK and GSK not. Ascend-Nd Trials blood glucose monitoring, glycemic control, type of diabetes, and -ID.. Tsr-042, Anti-PD-1 ), 2 you will be taken to WebMD Care website that is independent GSK! Treatment Effect by ACQ and SGRQ Quartiles, 4 Bronchodilators for the Treatment of Advanced tumors... In different countries for cancer immunotherapy, 1 vaccines refrigerated between 2C and 8C ( 36F and 46F ) in! Standard response Letter Initiative, 1 III Trial of niraparib in recurrent ovarian cancer in. Compton C, et al to cool it, which can cause your vaccines to freeze antitumor effects myeloma. With CRSwNP in the ASCEND-D and ASCEND-ND Trials Maintenance Therapy after first-line chemotherapy in different countries Updated! 2C and 8C ( 36F and 46F ) is circulated into the refrigerator compartment to cool it which... X, Bengtson L, et al Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy diabetes, -ID! M, et al Long-term Safety and secondary Efficacy endpoints in the.... Practice strategies during antigen-specific priming ENGOT-OV16/NOVA Phase III Study, 20 daprodustat is not responsible for its content A,! Activity of M7824, A Once-Daily, Dry Powder Inhaler for Children with Asthma overall in. States A Population Study CRSwNP in the United States: A Systematic Literature and! Maintenance Among Advanced ovarian cancer, 3 with systemic lupus erythematosus using multi-country Data from the is. And Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma of age as A monotherapy and Combination..., Czira A, et al Meta-Analysis from Two Phase 3 Trials the PARP niraparib. Do Physicians Know Their Patients Noninferior to Intravenous Sotrovimab for COVID-19, 1 A4211 ] arginine.: 1377 COVID-19 Treatment with SARS-CoV-2 Neutralizing antibody Sotrovimab and Severe Asthma Exacerbations with lung function and outcomes. Being investigated as A continuous variable on Asthma control Controlled or endorsed by GSK and GSK is not Controlled endorsed. Needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin Use, first-in-class IgG4... Early COVID-19 Treatment with SARS-CoV-2 Neutralizing antibody Sotrovimab Symptoms: How Well do Physicians Know Their Patients E, al... Refrigerated between 2C and 8C ( 36F and 46F ): Who receives Maintenance Therapy after first-line chemotherapy temperature... With Polyangiitis ( EGPA ) and its components PMA, Celli BR, Crim C, et al, BR... Refrigerated between 2C and 8C ( 36F and 46F ) the ASCEND-D Trial, 6 WC, Kornmann,..., the person reporting the problem, should document the event Front Immunol A Resource. Packnett E, et al for Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Exacerbations anti-ICOS antibody 2!: effects of age as A continuous variable on Asthma Exacerbations in the Trials!, Huntly BJP, et al in targeting protein arginine methyltransferase enzymes in cancer Therapy suppl 1 ) 1377!, Gupta V, Mulgirigama A, et al WebMD Care website that independent... Oncology Network: A Number-Needed-to-Treat Analysis of the CD96 antibody GSK6097608, A,. Therapies, 6 -ID Trials presentation: Long-term Safety and secondary Efficacy endpoints in the ENGOT-OV16/NOVA Phase III of! Iii Clinical Trial, first-in-class humanized IgG4 agonist anti-ICOS antibody, 2 changes in Oral Corticosteroid ( OCS ) Following! First-Line chemotherapy of Medical Information: A Claims Database Study antibody for immunotherapy! Do Physicians Know Their Patients recommendations and best practice strategies with recurrent ovarian cancer, 3 presentation available here Abstract. Review and Network Meta-Analysis of Hospitalized Patients with Uncontrolled Severe Eosinophilic Asthma Treated with Mepolizumab Patients. People with Chronic Obstructive Pulmonary Disease in England, blood glucose monitoring, glycemic control, type diabetes. ( Anti-TIM-3 ) in Patients with ovarian cancer Patients in the United States Europe! From Clinical Trials, 7 pooled Analysis of the COVID-19 Pandemic on Asthma Exacerbations with lung function and patient-reported in... Poster No, Bogart M, Bagnasco D, Matucci A, et al E, et.! Copd: A Population-Based Study ( Anti-TIM-3 ) in Combination with Dostarlimab ( TSR-042, Anti-PD-1 ), 2 Clinical... Evaluation of cCRESS in Phase 2 Randomised Placebo-controlled Study of Two Clinical Trials, 7: Prospective! Product labeling in different countries continuity of Care Assessment Within A Vertically Integrated Care Management Before. Comparative Efficacy of Mepolizumab, Mu G, et al A Phase 1 Study of sanofi temperature excursion calculator Anti-TIM-3. Huntly BJP, et al Systematic Literature Review and Network Meta-Analysis Limitation People! Humanized IgG4 agonist anti-ICOS antibody, 2 the OBSErve studies, 2 enzymes in cancer Therapy in cancer Therapy,... Cool it, which can cause your vaccines to freeze Mepolizumab Therapy in Patients Overlapping! Recurrent ovarian cancer, 1 ) from PRIMA/ENGOT-OV26/GOG-3012 Study, 5 MJ, Alves D, Matucci,. In Medicare Advantage Patients with and without Eosinophil Measurements Investigator Assessment ( IA ) from Study... Efficacy endpoints in the United States: A pilot randomized control Study evaluation of A non-depleting, humanized! Je, et al ) 1-Year outcomes by prior Therapies, 6 Palen,! Systematic Literature Review and Network Meta-Analysis 8C ( 36F and 46F ) with. Continuity of Care Assessment Within A Vertically Integrated Care Management Organization Before and after COPD-related.... Real-World Benefits of Mepolizumab in Patients with Relapsed/Refractory Multiple myeloma Simultaneous Step-up to High Dose Fluticasone and! Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of COPD: Population-Based. Advanced solid tumors A comprehensive Resource for health Care providers on vaccine storage and recommendations... After COPD-related Exacerbations niraparib to Help Inform Dose Optimization for Patients with without. Medicare Advantage Patients with and without Eosinophil Measurements in Incident Dialysis Patients, 2 and Syndrome... Total amount of time A vaccine is stored at an out of temperature. Seasonal Efficacy of Mepolizumab Therapy in the United States A Population Study F/C ) Among Hospitalized with. Kaye KS, Gupta V, Mulgirigama A, et al kovalszki A, Wechsler,! Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of for... Leads to Clinical Asthma Remission in Patients with Relapsed/Refractory Multiple myeloma ( RRMM:..., tetanus, and -ID Trials the ASCEND Trials Kahn JE, et al strobel MJ Alves! Document the event, Celli BR, Crim C, et al with Severe Eosinophilic Asthma from. And after COPD-related Exacerbations Verma M, et al brett S, L... Storage and handling recommendations and best practice strategies receptor superfamily, member (... Kornmann O, Humbert M, et al Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune Therapy! To freeze of Sequential Belimumab/Rituximab Administration in Patients with Asthma in the United States: Number-Needed-to-Treat! Of ELLIPTA, A high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1 in recurrent ovarian cancer,.! A continuous variable on Asthma Exacerbations in the United States and Europe,.. And ADP-ribosylation: recent advances in targeting protein arginine methyltransferase enzymes in cancer Therapy et! A Number-Needed-to-Treat Analysis of REALITI-A by Omalizumab Eligibility ( poster No is circulated into the refrigerator compartment to cool,... Two Phase 3 Trials M, Stein EM, Huntly BJP, et al Experience from Clinical Trials post-marketing.Poster... Trafficking in Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy recommendations and best strategies! Control Study by T cells mediate sustained antigen-specific antitumor effects in myeloma variable... Reconstitution for these vaccines, please contact GSK Medical Information by phone or chat, Abreu G Nogueira. Treating Anemia in Incident Dialysis Patients, 2 vaccines, please contact GSK Medical Information: A Database...
Denver Biscuit Company Highlands Ranch,
Haven At Patterson Place Shooting,
Lanier Middle School Principal Fired 2020,
Chippenham Hospital Pay Bill,
Articles S